Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer
Open Access
- 1 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Clinical and Translational Oncology
- Vol. 22 (11), 2074-2086
- https://doi.org/10.1007/s12094-020-02353-3
Abstract
Purpose Estrogen plays a critical role in the invasiveness and metastasis of non-small cell lung cancer (NSCLC) through estrogen receptor beta (ER beta). However, the antimetastatic effect of the ER beta antagonist fulvestrant was still limited in NSCLC patients. Recently, Toll-like receptor 4 (TLR4) signaling was implicated in NSCLC metastasis. Our present study aimed to evaluate the synergistic antimetastatic effect of a combination of fulvestrant and the TLR4-specific inhibitor CLI-095 (TAK-242) on human NSCLC cells. Methods The expression levels of ER beta and TLR4 were detected by immunohistochemical (IHC) analysis of 180 primary NSCLC and 30 corresponding metastatic lymph node samples. The association between ER beta and TLR4 expression was analyzed. The aggressiveness of NSCLC cells treated with fulvestrant, CLI-095 or the drug combination and formation status of their invadopodia, invasion-associated structures, were investigated. The protein levels in NSCLC cells in different groups were determined by Western blot and immunofluorescence analyses. Results Here, a positive correlation between ER beta and TLR4 expression was observed in both primary NSCLC tissue (Spearman's Rho correlation coefficient = 0.411, p < 0.001) and metastatic lymph node tissue (Spearman's Rho correlation coefficient = 0.374, p = 0.009). The protein levels of ER beta in NSCLC cell lines were decreased by fulvestrant, and this suppressive effect was significantly enhanced when fulvestrant was combined with CLI-095 (p < 0.05). Both the migration and invasion of NSCLC cells were suppressed by fulvestrant or CLI-095 alone, and the combination of fulvestrant + CLI-095 showed the strongest inhibitory effect (p < 0.05). In addition, the results demonstrated that CLI-095 also helped fulvestrant restrict the formation and function of invadopodia in NSCLC cells (p < 0.05). Conclusions Collectively, our study results suggested that CLI-095 enhances the antimetastatic effect of fulvestrant on NSCLC and provided support for further investigation of the antitumor activity of combined therapy with antiestrogen and anti-TLR4 agents in the clinic.Funding Information
- National Natural Science Foundation of China (81572277, 81272590)
This publication has 43 references indexed in Scilit:
- Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability fociNature Communications, 2013
- Estrogen synthesis and signaling pathways during aging: from periphery to brainTrends in Molecular Medicine, 2013
- 17β-Estradiol Promotes TLR4-Triggered Proinflammatory Mediator Production through Direct Estrogen Receptor α Signaling in Macrophages In VivoThe Journal of Immunology, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Cancer Cells Expressing Toll-like Receptors and the Tumor MicroenvironmentCancer Microenvironment, 2009
- Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancerLung Cancer, 2009
- Estrogen Receptor β Functions through Nongenomic Mechanisms in Lung Cancer CellsMolecular Endocrinology, 2009
- Invadopodia: Specialized Cell Structures for Cancer InvasionClinical & Experimental Metastasis, 2006
- Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Expression, Function, and Clinical Implications of the Estrogen Receptor β in Human Lung CancersBiochemical and Biophysical Research Communications, 2001